Blum Robert I sold $527K of CYTK

Studies in NEJM and Circulation show aficamten, a drug by Cytokinetics, improved symptoms and exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy (nHCM). The drug also altered heart structure and function, addressing a treatment gap. Long-term effects are under study. Cytokinetics funded the research.

Cytokinetics (CYTK) reported detailed Phase 3 trial results for aficamten, showing efficacy and safety in hypertrophic cardiomyopathy. The company plans to file a supplemental drug application, aiming to expand its cardiology franchise. Cytokinetics has a market cap of $10.3 billion and focuses on muscle-related diseases. Regulatory uncertainty and a small pipeline remain risks.

Cantor Fitzgerald reiterated an Overweight rating on Cytokinetics (CYTK), citing strong commercial and regulatory outlooks. The stock has risen 38% over the past year, trading at $73.62 with a $10.23B market cap. Analysts have raised earnings estimates, though profitability is not expected this year. Management expects 50% new prescription share by year-end and potential REMS relaxation. Cytokinetics reported Q2 sales of $25.3M for Myqorzo, exceeding estimates. Barclays and Citizens raised price

Cytokinetics (NASDAQ:CYTK) reported late-stage trial results for aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM), meeting primary goals of improving symptoms and quality of life. The study showed 53% of patients on aficamten improved in key areas vs. 13% on placebo, but lacked significant structural or cardiovascular benefits. The company plans a US marketing application in Q4 2026. Analysts forecast peak sales of over $5 billion for Myqorzo, but investors expressed concerns over

Cytokinetics (CYTK) presented additional results from ACACIA-HCM and MAPLE-HCM studies at the European Society of Cardiology Congress 2026, showing aficamten's benefits in non-obstructive HCM (nHCM) and superiority over metoprolol in obstructive HCM (oHCM). CYTK plans to submit an sNDA for aficamten in nHCM in Q4 2026. Myqorzo (aficamten) faces competition from Bristol Myers Squibb's (BMY) Camzyos and Edgewise Therapeutics' (EWTX) EDG-7500. CYTK shares are up 12.4% YTD, trading at 26.6X forward

Cytokinetics (NASDAQ:CYTK) reported positive results from its ACACIA-HCM Phase 3 trial of aficamten for non-obstructive hypertrophic cardiomyopathy, meeting primary endpoints and showing improvements in symptoms and exercise performance. The drug showed benefits in five key areas, but some safety concerns were noted. Cytokinetics plans to file for FDA approval in Q4 2026. Shares fell 3.19% to $69.79.